Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
Data to support potential sNDA submission for label expansion of IGALMI ® in the home setting
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
04:15pm, Tuesday, 04'th Mar 2025
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformat
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
11:00am, Tuesday, 04'th Mar 2025
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
03:33pm, Monday, 03'rd Mar 2025
NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformat
FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
07:00am, Friday, 28'th Feb 2025
NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
BioXcel Therapeutics Announces Reverse Stock Split
07:00am, Thursday, 06'th Feb 2025
NEW HAVEN, Conn., Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Monday, 23'rd Dec 2024
BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
08:16am, Friday, 22'nd Nov 2024
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop t
BioXcel Therapeutics Announces Proposed Public Offering
04:47pm, Thursday, 21'st Nov 2024
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop t
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
09:20am, Thursday, 14'th Nov 2024
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago.
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript
09:07am, Thursday, 14'th Nov 2024
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial O
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
07:00am, Friday, 08'th Nov 2024
NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
11:05am, Tuesday, 05'th Nov 2024
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics to Present at ThinkEquity Conference
07:00am, Tuesday, 29'th Oct 2024
NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
